Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2015

View Archived Issues

AC Immune collaborates with Janssen on anti-Tau vaccines for Alzheimer's

Mundipharma, Purdue and Esteve join forces to develop products for pain management

Amgen collaborates with MD Anderson to develop BiTE therapies for myelodysplastic syndrome

Celgene licenses ex-U.S. rights to Agios' AG-120

MedImmune licenses Omnis Pharmaceuticals oncolytic virus therapy

Precision Biologics discloses interim survival data for NPC-1C in metastatic colorectal cancer

Drug candidate induces host-protective immune cells in visceral leishmaniasis

Novel class of antibacterial compounds targeting Mur2 ligase described

Second Genome advances SGM-1019 in phase I trial

MaRS, J&J and Janssen to advance cardiac, diabetes and depression technologies

Mersana Therapeutics expands antibody-drug conjugate collaboration with Takeda

Sarepta gives updates on two DMD trials

OncoSec Medical to initiate pilot study in triple negative breast cancer

Companies forge immuno-oncology clinical trial collaborations

Promising results presented for chimeric antigen receptors in B-cell cancer treatment

Adimab expands collaboration with GSK, establishes new agreements

Tekmira Pharmaceuticals and OnCore Biopharma confirm merger agreement

Bayer researchers prepare new BUB1 inhibitors for cancer

Scientists at Lupin disclose novel CRAC modulators

New nicotinic acetylcholine receptor modulators designed by Lupin

Seragon patent reports new ER modulators for cancer

First biosimilar insulin agent approved in Japan

FDA grants orphan drug designation to SD-809 for Tourette's syndrome in children

Hospira submits BLA for epoetin alfa biosimilar Retacrit

FDA approves medical device to treat obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...